Menagen Signs a Commercialization Agreement with CKD for Biosimilar Darbepotein Alfa
Shots:
- The companies collaborated to commercialize the first biosimilar Darbepoetin alpha in the GCC market for the treatment of anemia associated with chronic renal failure. The CKD biosimilar is currently approved in South Korea
- The collaboration with CKD helps to build the biosimilar footprint in the Middle East and Africa markets to reach more people living with severe chronic diseases
- Menagen focuses to provide broad access to patients with unmet medical needs by utilizing its local expertise and capabilities and focus on various niche therapeutic products
Ref: Business Wire | Image: Business Wire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com